Actively Recruiting
68Ga-ICAM-1pep PET/CT in Cancer Patients
Led by Peking University Cancer Hospital & Institute · Updated on 2024-08-19
20
Participants Needed
1
Research Sites
66 weeks
Total Duration
On this page
Sponsors
P
Peking University Cancer Hospital & Institute
Lead Sponsor
P
Peking University Health Science Center
Collaborating Sponsor
AI-Summary
What this Trial Is About
This is an open-label positron emission tomography/computed tomography (PET/CT) study to investigate the clinical predictive value of 68Ga-ICAM-1pep in metastatic cancer patients receiving radiotherapy. A single dose of 2.96 MBq/kg body weight of 68Ga-ICAM-1pep will be injected intravenously. The visual and semiquantitative methods will be used to assess the PET/CT images.
CONDITIONS
Official Title
68Ga-ICAM-1pep PET/CT in Cancer Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 80 years
- ECOG performance status of 0 or 1
- Suspected or confirmed lung, esophagus, cervical, or other cancers recommended for PET/CT imaging by a clinician
You will not qualify if you...
- Pregnant or nursing women
- Severe liver or kidney dysfunction
- Low white blood cell count (less than 3 x 10^9/L)
- Unable to comply with PET/CT imaging procedures
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Beijing Cancer Hospital
Beijing, Beijing Municipality, China, 100142
Actively Recruiting
Research Team
T
Ting Zhang
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
DIAGNOSTIC
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here